Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

The duration of effectiveness of SARS-CoV-2 vaccination is not yet known. Here, the authors present preliminary evidence of BNT162b2 vaccine waning across all age groups above 16, with a higher incidence of infection in people who received their second dose early in 2021 compared to later in the yea...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Barak Mizrahi, Roni Lotan, Nir Kalkstein, Asaf Peretz, Galit Perez, Amir Ben-Tov, Gabriel Chodick, Sivan Gazit, Tal Patalon
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/e47630f157874a9797f16560d3dc86ff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e47630f157874a9797f16560d3dc86ff
record_format	dspace
spelling	oai:doaj.org-article:e47630f157874a9797f16560d3dc86ff2021-11-08T11:10:43ZCorrelation of SARS-CoV-2-breakthrough infections to time-from-vaccine10.1038/s41467-021-26672-32041-1723https://doaj.org/article/e47630f157874a9797f16560d3dc86ff2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-26672-3https://doaj.org/toc/2041-1723The duration of effectiveness of SARS-CoV-2 vaccination is not yet known. Here, the authors present preliminary evidence of BNT162b2 vaccine waning across all age groups above 16, with a higher incidence of infection in people who received their second dose early in 2021 compared to later in the year.Barak MizrahiRoni LotanNir KalksteinAsaf PeretzGalit PerezAmir Ben-TovGabriel ChodickSivan GazitTal PatalonNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-5 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Barak Mizrahi Roni Lotan Nir Kalkstein Asaf Peretz Galit Perez Amir Ben-Tov Gabriel Chodick Sivan Gazit Tal Patalon Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
description	The duration of effectiveness of SARS-CoV-2 vaccination is not yet known. Here, the authors present preliminary evidence of BNT162b2 vaccine waning across all age groups above 16, with a higher incidence of infection in people who received their second dose early in 2021 compared to later in the year.
format	article
author	Barak Mizrahi Roni Lotan Nir Kalkstein Asaf Peretz Galit Perez Amir Ben-Tov Gabriel Chodick Sivan Gazit Tal Patalon
author_facet	Barak Mizrahi Roni Lotan Nir Kalkstein Asaf Peretz Galit Perez Amir Ben-Tov Gabriel Chodick Sivan Gazit Tal Patalon
author_sort	Barak Mizrahi
title	Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
title_short	Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
title_full	Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
title_fullStr	Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
title_full_unstemmed	Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
title_sort	correlation of sars-cov-2-breakthrough infections to time-from-vaccine
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e47630f157874a9797f16560d3dc86ff
work_keys_str_mv	AT barakmizrahi correlationofsarscov2breakthroughinfectionstotimefromvaccine AT ronilotan correlationofsarscov2breakthroughinfectionstotimefromvaccine AT nirkalkstein correlationofsarscov2breakthroughinfectionstotimefromvaccine AT asafperetz correlationofsarscov2breakthroughinfectionstotimefromvaccine AT galitperez correlationofsarscov2breakthroughinfectionstotimefromvaccine AT amirbentov correlationofsarscov2breakthroughinfectionstotimefromvaccine AT gabrielchodick correlationofsarscov2breakthroughinfectionstotimefromvaccine AT sivangazit correlationofsarscov2breakthroughinfectionstotimefromvaccine AT talpatalon correlationofsarscov2breakthroughinfectionstotimefromvaccine
_version_	1718442385028939776

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

Ejemplares similares